RT Journal Article
T1 Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence.
A1 de-la-Rosa, David
A1 Martinez-Garcia, Miguel-Angel
A1 Olveira, Casilda
A1 Giron, Rosa
A1 Maiz, Luis
A1 Prados, Concepcion
K1 Pharmacoeconomics
K1 Pseudomonas aeruginosa
K1 Antibacterial agents
K1 Bronchiectasis
K1 Disease exacerbation
K1 Inhalation drug administration
AB Patients with bronchiectasis (BE) present exacerbations that increase with severity of the disease. We aimed to determine the annual cost of BE treatment according to its severity, determined by FACED score, as well as the parameters associated with higher costs. Multicentre historical cohorts study with patients from six hospitals in Spain. The costs arising during the course of a year from maintenance treatment, exacerbations, emergency visits and hospital admissions were analysed. In total, 456 patients were included (56.4% mild BE, 26.8% moderate BE and 16.9% severe BE). The mean cost was €4671.9 per patient, which increased significantly with severity. In mild BE, most of the costs were due to bronchodilators and inhaled steroids; in severe BE, most were due to exacerbations and inhaled antibiotics. Forced expiratory volume in 1 second (FEV1%), age, colonization by Pseudomonas aeruginosa and the number of admissions were independently related to higher costs. The highest costs were found in patients with BE associated with chronic obstructive pulmonary disease, with the most exacerbations and with chronic bronchial colonization by Pseudomonas aeruginosa (PA). In conclusion, BE patients gave rise to high annual costs, and these were doubled on each advance in severity on the FACED score. FEV1%, age, colonization by PA and the number of admissions were independently related to higher costs.
PB Sage Publications
YR 2016
FD 2016-07-07
LK https://hdl.handle.net/10668/24513
UL https://hdl.handle.net/10668/24513
LA en
NO de la Rosa D, Martínez-Garcia MA, Olveira C, Girón R, Máiz L, Prados C. Annual direct medical costs of bronchiectasis treatment: Impact of severity, exacerbations, chronic bronchial colonization and chronic obstructive pulmonary disease coexistence. Chron Respir Dis. 2016 Nov;13(4):361-371
DS RISalud
RD Apr 11, 2025